Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oliceridine · 2 trials · 1 indication
The NPRS is an 11-point scale from 0-10 where "0" = no pain and "10" = the most intense pain imaginable. A patient was a responder if: their final time-weighted Sum of Pain Intensity Difference (SPID)-24 corresponded to a ≥30% improvement without rescue pain medication during the Randomized Treatment Period, without early discontinuation of study medication for any reason, and without reaching the study medication dosing limit.
| Arm | Type | Description |
|---|---|---|
| Treatment 1 Oliceridine | EXPERIMENTAL | - |
| Treatment 2 Oliceridine | EXPERIMENTAL | - |
| Treatment 3 Oliceridine | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Morphine | ACTIVE_COMPARATOR | - |
| Treatment 4 Placebo | PLACEBO_COMPARATOR | - |
| Treatment 5 Morphine | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Oliceridine | DRUG | - |
| Placebo | DRUG | - |
| Morphine | DRUG | - |
Inclusion Criteria: * Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures. * Experiences a pain intensity rating of moderate to severe acute pain. * Able to provide written informed consent before any study proc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | N/A | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | - | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | - | Flozin |
Oliceridine is an investigational small molecule being developed for the treatment of moderate to severe acute pain. It has been studied in Phase 3 clinical trials for acute pain following surgical procedures such as bunionectomy and abdominoplasty.
Oliceridine is being developed by Trevena, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol TRVN.
Oliceridine is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, but the drug remains under investigation.
Oliceridine has been studied in two completed Phase 3 clinical trials: NCT02815709, which enrolled 418 participants with acute pain after bunionectomy, and NCT02820324, which enrolled 407 participants with acute pain after abdominoplasty. Both trials were randomized, double-blind, and placebo-controlled.
Yes, Oliceridine is also known as TRV130. The clinical trials for Oliceridine are titled 'Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain,' confirming that TRV130 is an alternative name for the drug.